The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

This review outlines the most frequently used rodent stroke models and discusses their
strengths and shortcomings. Mimicking all aspects of human stroke in one animal model is …

Despite the enormity of the societal and health burdens caused by Alzheimer's disease
(AD), there have been no FDA approvals for new therapeutics for AD since 2003. This …

It has been more than 100 years since Paul Ehrlich reported that various water-soluble dyes
injected into the circulation did not enter the brain. Since Ehrlich's first experiments, only a …

The blood–brain barrier (BBB) is a term used to describe a series of properties possessed
by the vasculature of the central nervous system (CNS) that tightly regulate the movement of …

Background Intracerebral hemorrhage (ICH) induces potently oxidative stress responses
and inflammatory processes. Isoliquiritigenin (ILG) is a flavonoid with a chalcone structure …

The blood-brain barrier (BBB) is composed of specialized endothelial cells that are critical to
neurological health. A key tool for understanding human BBB development and its role in …

The existence of blood–brain barrier (BBB) hampers the effective treatment of central
nervous system (CNS) diseases. Almost all macromolecular drugs and more than 98% of …

The blood-brain barrier (BBB) is formed by the endothelial cells of cerebral microvessels,
providing a dynamic interface between the peripheral circulation and the central nervous …